![]() | |
Clinical data | |
---|---|
Other names | (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl)propanoic acid |
Identifiers | |
| |
CAS Number | |
ChemSpider |
|
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H19NO5 |
Molar mass | 353.374 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
LY-341495 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as a potent and selective orthosteric antagonist for the group II metabotropic glutamate receptors (mGluR2/3).[1][2][3][4]
It is used in scientific research in several different areas, showing antidepressant effects in animal models,[5][6][7][8] increasing the behavioural effects of hallucinogenic drugs in animal tests,[9][10][11][12] and increasing the analgesic effects of μ-opioid agonists,[13][14] as well as modulating dopamine receptor function.[15][16][17]
The 1-fluorocyclopropane analog has a superior pharmacokinetic profile and similar mGluR2/3 affinity, and making a prodrug from this with the heptyl ester increases bioavailability still further.[18]